Background therapy in severe asthma on monoclonal antibody treatment in real life

IF 3.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Respiratory medicine Pub Date : 2025-02-01 DOI:10.1016/j.rmed.2025.107944

Filippo F. Cosini , Diego Bagnasco , Fulvio Braido , G. Walter Canonica , Giovanni Passalacqua , Elisa Testino , Manlio Milanese

{"title":"Background therapy in severe asthma on monoclonal antibody treatment in real life","authors":"Filippo F. Cosini , Diego Bagnasco , Fulvio Braido , G. Walter Canonica , Giovanni Passalacqua , Elisa Testino , Manlio Milanese","doi":"10.1016/j.rmed.2025.107944","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Global Initiative for Asthma (GINA) recently recommends clinicians to reduce inhaled corticosteroid doses in patients with severe asthma who respond positively to monoclonal antibodies (MAbs).</div></div><div><h3>Objective</h3><div>As we operated this reduction even before the document, we analysed our cohort of subjects on treatment with a MAbs for at least 24 months.</div></div><div><h3>Methods</h3><div>Data stored in our electronic archive and at the 6-month follow-up (FU) were registered and patients’ adherence to asthma therapy was derived by electronic pharmacy claim database.</div></div><div><h3>Results</h3><div>Sixty-three subjects were enrolled. A complete asthma remission and reduction to GINA Step 3 was obtained in 41 % and 61 % of them, respectively. Non-adherent subjects to inhaled and oral asthma therapy were 45 % of them, with a higher percentage among those in complete remission (59 % vs 33 %).</div></div><div><h3>Conclusion</h3><div>In our cohort<strong>,</strong> stepping down asthma therapy from 5 to 3 level in severe asthmatic patients on Mabs is without any negative consequences on asthma control, even in the case of non-adherence.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"237 ","pages":"Article 107944"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095461112500006X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Global Initiative for Asthma (GINA) recently recommends clinicians to reduce inhaled corticosteroid doses in patients with severe asthma who respond positively to monoclonal antibodies (MAbs).

Objective

As we operated this reduction even before the document, we analysed our cohort of subjects on treatment with a MAbs for at least 24 months.

Methods

Data stored in our electronic archive and at the 6-month follow-up (FU) were registered and patients’ adherence to asthma therapy was derived by electronic pharmacy claim database.

Results

Sixty-three subjects were enrolled. A complete asthma remission and reduction to GINA Step 3 was obtained in 41 % and 61 % of them, respectively. Non-adherent subjects to inhaled and oral asthma therapy were 45 % of them, with a higher percentage among those in complete remission (59 % vs 33 %).

Conclusion

In our cohort, stepping down asthma therapy from 5 to 3 level in severe asthmatic patients on Mabs is without any negative consequences on asthma control, even in the case of non-adherence.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory medicine 医学-呼吸系统

CiteScore

7.50

自引率

0.00%

发文量

199

审稿时长

38 days

期刊介绍： Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.